Skip to Main Content

The Food and Drug Administration told Amicus Therapeutics (FOLD) that it lacks sufficient clinical data on an experimental treatment for Pompe disease to submit a marketing application, the company said Monday.

The regulatory setback means Amicus will have to wait until 2019 to seek U.S. approval for the drug, called AT-GAA — after clinical data in additional Pompe patients are collected.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!